Quick Answer
ADC Therapeutics SA reported Operating Income of -$121.50 million for fiscal year 2025.
ADC Therapeutics SA Operating Income — Annual History
| Fiscal Year | Operating Income | YoY Change |
|---|---|---|
| 2025 | -$121.50M | +7.0% |
| 2024 | -$130.65M | +21.3% |
| 2023 | -$165.99M | -34.6% |
| 2022 | -$123.34M | — |
Quarterly Operating Income
| Quarter Ending | Operating Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$30.97M | +12.9% | +29.9% |
| June 30, 2025 | -$44.15M | -52.0% | -55.1% |
| March 31, 2025 | -$28.46M | +15.3% | +20.0% |
| September 30, 2024 | -$35.56M | +1.6% | -22.5% |
| June 30, 2024 | -$29.04M | +26.8% | +13.6% |
| March 31, 2024 | -$33.61M | +33.1% | +7.0% |
| September 30, 2023 | -$36.15M | — | +8.8% |
| June 30, 2023 | -$39.65M | — | +21.0% |
- ADC Therapeutics SA showed an increase of +7.0% in Operating Income compared to the prior fiscal year.
- Over the 2022–2025 period, ADC Therapeutics SA’s operating income has grown by 1.5% (from -$123.34 million to -$121.50 million).
- The most recent figure is from ADC Therapeutics SA’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: